Allogeneic Bone Marrow Transplantation in Multiple Myeloma
Open Access
- 31 October 1991
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 325 (18), 1267-1273
- https://doi.org/10.1056/nejm199110313251802
Abstract
In contrast to autologous bone marrow transplants for hematologic cancers, allogeneic transplants contain no tumor cells that might cause a relapse. We report the results of such allogeneic bone marrow transplantation using HLA-compatible sibling donors in 90 patients with multiple myeloma performed in 26 European centers between 1983 and 1989. At the time of the most recent follow-up, 79 months after the start of the study, 47 patients were alive and 43 were dead. The rate of complete remission after bone marrow transplantation was 43 percent for all patients and 58 percent for the patients who had engraftment. The actuarial survival at 76 months was 40 percent. The median duration of relapse-free survival among patients who were in complete remission after bone marrow transplantation was 48 months. The stage of the disease at diagnosis and the number of treatment regimens tried before bone marrow transplantation were predictive of the likelihood of complete remission after engraftment. There were trends toward longer survival among patients who were responsive to treatment before bone marrow transplantation, patients with Stage I disease at diagnosis, and patients who had received only first-line treatment before transplantation, as compared with those who were not responsive, those with Stage II or III disease at diagnosis, and those who had received three or more lines of treatment, but the differences in these factors were not statistically significant. Two post-transplantation factors predicted better long-term survival: complete remission after engraftment and grade I graft-versus-host disease, rather than grade II, III, or IV. Allogeneic bone marrow transplantation with the use of HLA-matched sibling donors appears to be a promising method of treatment for some patients with multiple myeloma. (N Engl J Med 1991;325:1267–73.)This publication has 35 references indexed in Scilit:
- High‐dose dexamethasone for refractory or relapsing multiple myelomaAmerican Journal of Hematology, 1991
- Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction ChemotherapyNew England Journal of Medicine, 1990
- Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III —A randomized study from MGCSEuropean Journal of Haematology, 1989
- ErratumBritish Journal of Haematology, 1988
- Allogeneic bone marrow transplantation in 24 patients with multiple myeloma reported to the ebmt registryHematological Oncology, 1988
- Bone Marrow Transplantation in Three Patients with Multiple MyelomaActa Medica Scandinavica, 1986
- Autologous Bone Marrow Transplantation in Patients with Acute Nonlymphocytic Leukemia, Using ex Vivo Marrow Treatment with 4-HydroperoxycyclophosphamideNew England Journal of Medicine, 1986
- Bone Marrow Transplantation for Patients with Chronic Myeloid LeukemiaNew England Journal of Medicine, 1986
- Antileukemic Effect of Chronic Graft-versus-Host DiseaseNew England Journal of Medicine, 1981
- Chronic Myelogenous Leukemia — New ConceptsNew England Journal of Medicine, 1981